1. Home
  2. LXFR vs ADCT Comparison

LXFR vs ADCT Comparison

Compare LXFR & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Luxfer Holdings PLC

LXFR

Luxfer Holdings PLC

HOLD

Current Price

$12.19

Market Cap

421.4M

Sector

Industrials

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.72

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXFR
ADCT
Founded
1898
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
421.4M
484.4M
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
LXFR
ADCT
Price
$12.19
$3.72
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.75
AVG Volume (30 Days)
230.8K
734.4K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
4.26%
N/A
EPS Growth
N/A
30.86
EPS
0.28
N/A
Revenue
$384,600,000.00
$81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.01
$66.49
P/E Ratio
$43.61
N/A
Revenue Growth
N/A
14.85
52 Week Low
$9.41
$1.05
52 Week High
$16.03
$4.98

Technical Indicators

Market Signals
Indicator
LXFR
ADCT
Relative Strength Index (RSI) 43.92 41.55
Support Level $11.32 $3.65
Resistance Level $12.71 $3.88
Average True Range (ATR) 0.43 0.22
MACD 0.12 -0.04
Stochastic Oscillator 55.21 35.82

Price Performance

Historical Comparison
LXFR
ADCT

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: